SS18-SSX drives CREB activation in synovial sarcoma
Open Access
- 12 May 2022
- journal article
- research article
- Published by Springer Nature in Cellular Oncology
- Vol. 45 (3) , 399-413
Abstract
Purpose: Synovial sarcoma (SySa) is a rare soft tissue tumor characterized by a reciprocal t(X;18) translocation. The chimeric SS18-SSX fusion protein represents the major driver of the disease, acting as aberrant transcriptional dysregulator. Oncogenic mechanisms whereby SS18-SSX mediates sarcomagenesis are incompletely understood, and strategies to selectively target SySa cells remain elusive. Based on results of Phospho-Kinase screening arrays, we here investigate the functional and therapeutic relevance of the transcription factor CREB in SySa tumorigenesis. Methods: Immunohistochemistry of phosphorylated CREB and its downstream targets (Rb, Cyclin D1, PCNA, Bcl-xL and Bcl-2) was performed in a large cohort of SySa. Functional aspects of CREB activity, including SS18-SSX driven circuits involved in CREB activation, were analyzed in vitro employing five SySa cell lines and a mesenchymal stem cell model. CREB mediated transcriptional activity was modulated by RNAi-mediated knockdown and small molecule inhibitors (666-15, KG-501, NASTRp and Ro 31-8220). Anti-proliferative effects of the CREB inhibitor 666-15 were tested in SySa avian chorioallantoic membrane and murine xenograft models in vivo. Results: We show that CREB is phosphorylated and activated in SySa, accompanied by downstream target expression. Human mesenchymal stem cells engineered to express SS18-SSX promote CREB expression and phosphorylation. Conversely, RNAi-mediated knockdown of SS18-SSX impairs CREB phosphorylation in SySa cells. Inhibition of CREB activity reduces downstream target expression, accompanied by suppression of SySa cell proliferation and induction of apoptosis invitro and in vivo. Conclusion: In conclusion, our data underline an essential role of CREB in SySa tumorigenesis and provides evidence for molecular targeted therapies.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (HA4441/2-1)
- Wilhelm Sander-Stiftung (2016.099.1)
- Medizinische Fakultät, Westfälische Wilhelms-Universität Münster (HU121421, TR121716, TR122011)
- Universitätsklinikum Münster
This publication has 55 references indexed in Scilit:
- Reversible Disruption of mSWI/SNF (BAF) Complexes by the SS18-SSX Oncogenic Fusion in Synovial SarcomaCell, 2013
- SS18 Together with Animal-Specific Factors Defines Human BAF-Type SWI/SNF ComplexesPLOS ONE, 2012
- Phosphatidylinositol‐3′‐kinase/AKT signaling is essential in synovial sarcomaInternational Journal of Cancer, 2010
- Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes regionBMC Cancer, 2010
- Cyclic AMP Response Element-Binding Protein Overexpression: A Feature Associated with Negative Prognosis in Never Smokers with Non–Small Cell Lung CancerCancer Research, 2008
- Synovial Sarcoma: From Genetics to Genetic-based Animal ModelingClinical Orthopaedics and Related Research, 2008
- Histone Deacetylase Inhibitors Reverse SS18-SSX–Mediated Polycomb Silencing of the Tumor Suppressor Early Growth Response 1 in Synovial SarcomaCancer Research, 2008
- Growth Suppression of Lung Cancer Cells by Targeting Cyclic AMP Response Element-Binding ProteinCancer Research, 2008
- The Transcriptional Coactivators p300 and CBP Are Histone AcetyltransferasesCell, 1996
- Phosphorylation-induced binding and transcriptional efficacy of nuclear factor CREBNature, 1988